BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
일요일, 9월 27

Elicio Therapeutics Inc

ELTXNASDAQ
Trade with Public
Trade with Public
$1.84
-0.04-2.13%
가까이에: Sep 25, 5:00 PM EST
$1.85
0.0150.82%
시간외: Sep 25, 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Elicio Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elicio Therapeutics (ELTX).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

4Buy
1Hold
Consensus RatingBuy# Analysts5Avg. Consensus PT$15Upside to Avg. PT+699.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026B. Riley SecuritiesMayank MamtaniPT CutBuy$27→$8
Aug 18, 2026HC Wainwright & Co.Robert BurnsMaintainedBuy$23
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8

B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $23 price target.
Benzinga Newsdesk

PRO
Ladenburg Thalmann Assumes Elicio Therapeutics at Buy, Announces Price Target of $12

Ladenburg Thalmann analyst Kevin DeGeeter assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Jones Trading Downgrades Elicio Therapeutics to Hold

Jones Trading analyst Boris Peaker downgrades Elicio Therapeutics (NASDAQ:ELTX) from Buy to Hold.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $23

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price target from $17 to $23.
Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27

B. Riley Securities analyst Mayank Mamtani initiates coverage on Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $27.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved